Back to User profile » Dr Kamal Hamed
Papers published by Dr Kamal Hamed:
![Plain language summary](assets/img/article_icons/plain-language.png)
No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials [Erratum]
Hamed K, Wiktorowicz T, Assadi Gehr M
Infection and Drug Resistance 2020, 13:3461-3462
Published Date: 7 October 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials
Hamed K, Wiktorowicz T, Assadi Gehr M
Infection and Drug Resistance 2020, 13:3209-3215
Published Date: 16 September 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015
Santerre Henriksen A, Smart JI, Hamed K
Infection and Drug Resistance 2018, 11:1309-1320
Published Date: 28 August 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
Hamed K, Conti V, Tian H, Loefroth E
Patient Preference and Adherence 2017, 11:831-838
Published Date: 27 April 2017
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections
Gonzalez-Ruiz A, Seaton RA, Hamed K
Infection and Drug Resistance 2016, 9:47-58
Published Date: 15 April 2016